JP2010509920A5 - - Google Patents

Download PDF

Info

Publication number
JP2010509920A5
JP2010509920A5 JP2009537358A JP2009537358A JP2010509920A5 JP 2010509920 A5 JP2010509920 A5 JP 2010509920A5 JP 2009537358 A JP2009537358 A JP 2009537358A JP 2009537358 A JP2009537358 A JP 2009537358A JP 2010509920 A5 JP2010509920 A5 JP 2010509920A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
variable region
chain variable
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009537358A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509920A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/084792 external-priority patent/WO2008076560A2/en
Publication of JP2010509920A publication Critical patent/JP2010509920A/ja
Publication of JP2010509920A5 publication Critical patent/JP2010509920A5/ja
Withdrawn legal-status Critical Current

Links

JP2009537358A 2006-11-15 2007-11-15 Ｂｔｌａに対するヒトモノクローナル抗体および使用方法 Withdrawn JP2010509920A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86605806P 2006-11-15 2006-11-15
PCT/US2007/084792 WO2008076560A2 (en) 2006-11-15 2007-11-15 Human monoclonal antibodies to btla and methods of use

Publications (2)

Publication Number Publication Date
JP2010509920A JP2010509920A (ja) 2010-04-02
JP2010509920A5 true JP2010509920A5 (enExample) 2010-05-13

Family

ID=39536943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009537358A Withdrawn JP2010509920A (ja) 2006-11-15 2007-11-15 Ｂｔｌａに対するヒトモノクローナル抗体および使用方法

Country Status (17)

Country Link
US (2) US8247537B2 (enExample)
EP (1) EP2097447A4 (enExample)
JP (1) JP2010509920A (enExample)
KR (1) KR20090088891A (enExample)
CN (1) CN101578296A (enExample)
AR (1) AR063840A1 (enExample)
AU (1) AU2007334264A1 (enExample)
CA (1) CA2669921A1 (enExample)
CL (1) CL2007003291A1 (enExample)
EA (1) EA200970477A1 (enExample)
IL (1) IL198729A0 (enExample)
MX (1) MX2009005189A (enExample)
NO (1) NO20092285L (enExample)
NZ (1) NZ577085A (enExample)
TW (1) TW200837081A (enExample)
WO (1) WO2008076560A2 (enExample)
ZA (1) ZA200903775B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349320B2 (en) 2004-12-09 2013-01-08 La Jolla Institute For Allergy And Immunology Compositions and methods for modulating responses mediated or associated with BTLA activity
EA200970477A1 (ru) 2006-11-15 2009-12-30 Медарекс, Инк. Человеческие моноклональные антитела к btla и способы применения
EP2408818A1 (en) * 2009-03-17 2012-01-25 Université de la Méditerranée Btla antibodies and uses thereof
RU2011149798A (ru) 2009-05-08 2013-06-20 Дженентек, Инк. Гуманизированные анти-egfl7-антитела и способы их применения
US8303952B2 (en) * 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance
IN2012DN00863A (enExample) * 2009-07-31 2015-07-10 Medarex Inc
HRP20180928T1 (hr) * 2012-03-28 2018-07-27 Sanofi Protutijela za ligande bradikinin b1 receptora
MY199321A (en) * 2013-05-30 2023-10-24 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
HK1221964A1 (zh) * 2013-05-31 2017-06-16 Sorrento Therapeutics, Inc. 与pd-1结合的抗原结合蛋白
WO2015007887A1 (en) * 2013-07-19 2015-01-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of a ligand of hvem and an immunotoxin for use in therapy
LT3030262T (lt) 2013-08-08 2020-03-10 Cytune Pharma Kombinuota farmacinė kompozicija
EP3995507B1 (en) 2013-08-08 2023-10-04 Cytune Pharma Il-15 and il-15ralpha sushi domain based on modulokines
CN104974253A (zh) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
US20160355589A1 (en) * 2014-08-19 2016-12-08 Merck Sharp & Dohme Corp. Anti-tigit antibodies
KR102669985B1 (ko) 2015-06-30 2024-05-29 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 Btla 융합 단백질 작용제 및 이의 용도
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MY198562A (en) 2015-11-03 2023-09-05 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
WO2017096017A1 (en) * 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
CN108699154A (zh) * 2016-02-26 2018-10-23 国家医疗保健研究所 对btla具有特异性的抗体及其用途
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018014001A1 (en) 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
WO2018068756A1 (en) * 2016-10-14 2018-04-19 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric btla
AU2017351764A1 (en) * 2016-10-25 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Monoclonal antibodies binding to the CD160 transmembrane isoform
CN107043419A (zh) * 2016-12-13 2017-08-15 无锡傲锐东源生物科技有限公司 抗btla蛋白单克隆抗体及其用途
CN108218987B (zh) * 2016-12-21 2019-08-20 南京金斯瑞生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人ctla4抗体
JOP20190261A1 (ar) * 2017-05-19 2019-11-05 Lilly Co Eli أجسام مضادة لعامل مساعد لـ btla واستخداماتها
AU2018277545B2 (en) 2017-05-31 2025-05-15 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
US11542331B2 (en) 2017-06-06 2023-01-03 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
CA3061959A1 (en) 2017-06-09 2018-12-13 Providence Health & Services - Oregon Utilization of cd39 and cd103 for identification of human tumor reactive t cells for treatment of cancer
WO2019036855A1 (en) * 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
IL275391B2 (en) * 2017-12-20 2025-05-01 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN112566935B (zh) 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
CN112533948B (zh) * 2018-05-31 2025-01-14 台湾醣联生技医药股份有限公司 与双触角Lewis B以及Lewis Y抗原结合的治疗性抗体
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体
CN115141279B (zh) * 2018-09-26 2025-08-19 福州拓新天成生物科技有限公司 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
WO2020232051A1 (en) * 2019-05-15 2020-11-19 Biosion Inc. Antibody binding csf-1r and use thereof
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN114457025A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达btla阻断物的多能干细胞或其衍生物及应用
CN114657137A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达靶向BTLA的shRNA和/或shRNA-miR的多能干细胞或其衍生物
CN115073599B (zh) * 2021-03-16 2023-04-28 北京天广实生物技术股份有限公司 结合pd-l1的抗体及其用途
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
WO2022214653A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
AU2022288058A1 (en) 2021-06-07 2023-11-16 Agonox, Inc. Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
AU2023212896A1 (en) * 2022-01-29 2024-08-22 Hifibio, Inc. Antibody against btla and uses thereof
EP4558226A1 (en) * 2022-07-19 2025-05-28 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
JP2004532038A (ja) 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
EP1498485A4 (en) 2002-04-09 2006-09-06 Kyowa Hakko Kogyo Kk MODIFIED GENOME CELLS
EP1539218A4 (en) * 2002-06-20 2007-08-22 Univ California COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
UA115960C2 (uk) * 2003-07-15 2018-01-25 Емджен, Інк., Людські анти-ngf нейтралізуючі антитіла як селективні інгібітори метаболічних шляхів фактора росту нервової тканини (ngf)
WO2006054961A2 (en) * 2004-11-12 2006-05-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EA200970477A1 (ru) 2006-11-15 2009-12-30 Медарекс, Инк. Человеческие моноклональные антитела к btla и способы применения
US8303952B2 (en) * 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance

Similar Documents

Publication Publication Date Title
JP2010509920A5 (enExample)
JP2016006123A5 (enExample)
JP2013150606A5 (enExample)
JP2008544755A5 (enExample)
CN108348601B (zh) 与lag3结合的抗体治疗剂
CN110914303B (zh) 结合lag-3的抗体及其用途
US20210009688A1 (en) Anti-pd-1 antibody and use thereof
EP3459597B1 (en) Single domain antibody for ctla4 and derived protein thereof
US11225522B2 (en) Single domain antibody and derivative proteins thereof against programmed death-ligand (PDL1)
JP2009155338A5 (enExample)
JP2010513303A5 (enExample)
JP2011036254A5 (enExample)
JP2014506120A5 (enExample)
JP7493254B2 (ja) Ｐｄ－１結合抗体及びその用途
JP2005522514A5 (enExample)
JP2013227339A5 (enExample)
JP2018527919A5 (enExample)
JP2019500893A5 (enExample)
JP2003532409A5 (enExample)
JP2004534020A5 (enExample)
JP2008509223A5 (enExample)
JP2009297037A5 (enExample)
CN106478819B (zh) 一种针对pd-l1的单克隆抗体或抗体片段
JPWO2020043152A5 (enExample)
JP2020528765A5 (enExample)